Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2007 by Harrold van Barlingen, Thuja Capital is an early-stage venture capital firm based in Utrecht, Netherlands. The firm focuses on investing in life science companies across Europe, with a portfolio of 24 companies. Their investment strategy emphasizes translating scientific advancements into clinical applications.
Thuja Capital invests in pre-seed and seed-stage biotech and medtech companies that tackle significant unmet medical needs. They provide financial backing along with strategic, technical, and operational support to help startups navigate early challenges and achieve critical milestones.
Notable portfolio companies include ArgenX, Alesta Therapeutics, and CardiacBooster, among others. The firm has backed a total of 24 companies in the life sciences sector.
Email info@thujacapital.com with your deck to pitch them directly.
As of 2024, Thuja Capital published their Impact & ESG Annual Report, highlighting their commitment to transparency and accountability in investment practices.
Yes, Thuja Capital often leads investment rounds in the companies they back, providing both capital and strategic guidance.
Thuja Capital is open to follow-on investments, particularly for companies that demonstrate significant progress and potential in addressing unmet medical needs.
Specific fund size details are not disclosed, but the firm focuses on early-stage investments in the biotech and healthcare sectors.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.